MajorAntiretroviral, HIV protease inhibitor×Locally acting glucocorticoid (inhaled, nasal, intestinal and oesophageal formulations)
Updated · Methodology
Mechanism
CYP3A4 is the main enzyme that metabolises budesonide (budesonide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Atazanavir inhibits this enzyme, and ritonavir, part of the recommended atazanavir regimen, inhibits it more strongly than atazanavir (atazanavir SmPC, European Medicines Agency, EMA). The US budesonide label lists atazanavir among strong CYP3A4 inhibitors (US Food and Drug Administration, FDA). When intranasal fluticasone propionate, another corticosteroid, was given for 7 days with ritonavir 100 mg twice daily, fluticasone levels rose significantly. Endogenous cortisol fell by about 86% (EMA). The atazanavir SmPC says the same could occur with other corticosteroids metabolised by CYP3A, such as budesonide. It expects the same effects from inhaled and nasal corticosteroids when atazanavir is taken without ritonavir, too (EMA). The documents give no figures for budesonide with atazanavir.
Symptoms
CYP3A inhibitors, including human immunodeficiency virus (HIV) protease inhibitors, are expected to increase the risk of systemic adverse reactions to budesonide. This has limited clinical relevance in short-term treatment (1–2 weeks) and is taken into account in long-term treatment (budesonide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cushing's syndrome and adrenal suppression have been reported in people who took ritonavir with inhaled or intranasal fluticasone. The atazanavir SmPC says this could also occur with budesonide (atazanavir SmPC, European Medicines Agency, EMA). Inhaled corticosteroids can cause systemic effects, especially at high doses over long periods: Cushing's syndrome and cushingoid features, adrenal suppression, growth retardation in children and adolescents, decreased bone mineral density, cataract and glaucoma (AEMPS).
Management
Atazanavir with ritonavir is not recommended with glucocorticoids metabolised by CYP3A4, including budesonide, unless the potential benefit outweighs the risk of systemic corticosteroid effects. These effects include Cushing's syndrome and adrenal suppression (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA). Consider reducing the glucocorticoid dose with close monitoring of local and systemic effects, or switching to a glucocorticoid that is not a CYP3A4 substrate, such as beclometasone. When the glucocorticoid is withdrawn, the dose may need to be tapered over a longer period (EMA). Use inhaled and nasal corticosteroids with caution with atazanavir, with or without ritonavir, and consider alternatives, particularly for long-term use (EMA). For atazanavir with cobicistat, budesonide is on the list of corticosteroids not recommended unless the benefit outweighs the risk. If they are still used together, patients are monitored for systemic reactions. Corticosteroids less dependent on CYP3A, such as nasal or inhaled beclometasone, are considered, particularly for long-term use (atazanavir/cobicistat SmPC, EMA). The inhaled budesonide SmPC advises avoiding combinations with human immunodeficiency virus (HIV) protease inhibitors and other CYP3A inhibitors unless the benefit outweighs the risk of systemic reactions. If they are combined, patients are monitored for these reactions, and a lower budesonide dose can be considered (budesonide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The SmPC of budesonide gastro-resistant capsules advises avoiding combinations with CYP3A4 inhibitors and names ritonavir explicitly among the strong inhibitors (AEMPS, sections 4.4 and 4.5). Refer to the ritonavir SmPC as well before starting atazanavir with ritonavir (EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Reyataz (atazanavir) prescribing information (2024)– DailyMed setid 165cff62-b284-4a27-a65d-9ec8a5bfcdd8, revisión 12/2024, secciones 4 y 7.3
- AEMPS: Ficha técnica: Budesonida, Intestifalk 3 mg cápsulas gastrorresistentes (nº registro 65849), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 65849, revisión 06/2026, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Budesonida, Pulmicort Turbuhaler 200 microgramos (nº registro 59254), secciones 4.4 y 4.5 (2023)– AEMPS, CIMA, nº registro 59254, revisión 04/2023, secciones 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat (EU/1/15/1025), sección 4.5 (2026)– EMA, Evotaz 300 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, secciones 4.3 y 4.5
- EMA: Ficha técnica: Atazanavir, Reyataz (EU/1/03/267), sección 4.4 (2026)– EMA, Reyataz 300 mg cápsulas (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03267008, consultada 11/2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5 (CORTICOSTEROIDES)
- FDA: Evotaz (atazanavir and cobicistat) prescribing information (2025)– FDA, DailyMed setid 83db29d7-5d85-49d6-8cb6-740473365cf8 (E.R. Squibb & Sons), version 16, revised 05/2025, sections 4 and 7.3 (Corticosteroids)
- FDA: Pulmicort Respules (budesonide) prescribing information (2019)– FDA, DailyMed setid 33cd9834-76df-4f26-3fa2-aab6b9eee8f2 (AstraZeneca Pharmaceuticals LP), version 23, revised 10/2019, sections 5.12 and 7.1